Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalaprilat Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalaprilat Anhydrous SCHEMBL12737170 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL18033873 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL2406720 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL3090322 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL11204535 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL24327564 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL6106603 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8149345 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL21046169 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL37288 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11195 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4595974-A2 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE | Carlson, William D. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| US-4663307-A | Anti-allergic and anti-thromboembolic 6H-dibenz-[b,e][1,4]-oxathiepin derivatives, compositions, and method of use therefor | MERCK FROSST CANADA, INC. (CA) | 1987-05-05 | — | — | US | claimed |
| EP-0220107-A2 | Use of angiotensin-converting enzyme inhibitors in macular degeneration | MERCK & CO. INC. (US) | 1987-04-29 | — | — | EP | claimed |
| US-4656188-A | Ace inhibitors in macular degeneration | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | claimed |
| EP-0166257-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | claimed |
| EP-0160307-A2 | Angiotensin converting enzyme inhibitors useful in the treatment of renal diseases | MERCK & CO. INC. (US) | 1985-11-06 | — | — | EP | claimed |
| EP-0129136-A2 | Antihypertensive composition | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4472384-A | INTERPHENYLENE 9-THIA-11-OXO-12-AZA PROSTANOIC ACID DERIVATIVE AND CARBOXYALKYLDIPEPTIDE | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0079521-A1 | Process for preparation of carboxyalkyldipeptide derivatives | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | claimed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | claimed |